Metrics to compare | CINPHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINPHAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | 233.2x | −0.2x | |
PEG Ratio | 0.02 | 1.81 | 0.00 | |
Price/Book | 8.0x | 9.6x | 2.6x | |
Price / LTM Sales | 19.3x | 7.1x | 2.7x | |
Upside (Analyst Target) | 296.8% | 0.0% | 68.5% | |
Fair Value Upside | Unlock | 21.6% | 11.5% | Unlock |
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.